AR091722A1 - Forma cristalina de un derivado de indolinona y su uso - Google Patents
Forma cristalina de un derivado de indolinona y su usoInfo
- Publication number
- AR091722A1 AR091722A1 ARP130102452A AR091722A1 AR 091722 A1 AR091722 A1 AR 091722A1 AR P130102452 A ARP130102452 A AR P130102452A AR 091722 A1 AR091722 A1 AR 091722A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystal form
- indolinone derivative
- crystalline
- indolinone
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Un derivado de indolinona cristalino como se muestra en la descripción, un proceso para su fabricación, y su uso en una terapia frente a la proliferación celular. Reivindicación 1: Etilamida del ácido 3-{3-[1-(4-dimetilaminometil-fenilamino)-1-fenil-met-(Z)-iliden]-2-oxo-2,3-dihidro-1H-indol-6-il}-propinoico caracterizada porque tiene la fórmula (1) o un tautómero o sal farmacéuticamente aceptable de este, en particular en forma cristalina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12176036 | 2012-07-11 | ||
EP12179105 | 2012-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091722A1 true AR091722A1 (es) | 2015-02-25 |
Family
ID=48747583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102452 AR091722A1 (es) | 2012-07-11 | 2013-07-10 | Forma cristalina de un derivado de indolinona y su uso |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140018372A1 (es) |
AR (1) | AR091722A1 (es) |
TW (1) | TW201416350A (es) |
UY (1) | UY34902A (es) |
WO (1) | WO2014009318A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
CN104109159A (zh) | 2013-04-17 | 2014-10-22 | 杭州普晒医药科技有限公司 | 苯磺酰胺噻唑化合物的新晶型及其制备方法 |
US9758471B2 (en) | 2014-06-02 | 2017-09-12 | Sun Pharmaceutical Industries Limited | Process for the preparation of 4-dimethylaminocrotonic acid |
ES2751925T3 (es) * | 2014-07-14 | 2020-04-02 | Univ Zuerich Prorektorat Mnw | Medios y procedimientos para identificar a un paciente que tiene un cáncer positivo para BRAF como un paciente que no responde al tratamiento con un inhibidor de BRAF y como un paciente que responde al tratamiento con un inhibidor de MAPK/ERK |
CN105439879B (zh) * | 2014-08-07 | 2018-08-10 | 天津法莫西医药科技有限公司 | 一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
US10572185B2 (en) * | 2018-06-01 | 2020-02-25 | Western Digital Technologies, Inc. | Non-volatile storage system with command replay |
CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2016049A1 (en) | 2006-04-24 | 2009-01-21 | Boehringer Ingelheim International GmbH | 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors |
US20100184747A1 (en) | 2007-06-12 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Indoline derivatives and their use in treating disease-states such as cancer |
KR20110039474A (ko) | 2008-07-29 | 2011-04-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 화합물 |
EP2640860A4 (en) * | 2010-11-19 | 2014-06-04 | Univ California | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
-
2013
- 2013-07-08 WO PCT/EP2013/064401 patent/WO2014009318A1/en active Application Filing
- 2013-07-09 US US13/937,432 patent/US20140018372A1/en not_active Abandoned
- 2013-07-10 AR ARP130102452 patent/AR091722A1/es unknown
- 2013-07-10 TW TW102124794A patent/TW201416350A/zh unknown
- 2013-07-11 UY UY0001034902A patent/UY34902A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2014009318A1 (en) | 2014-01-16 |
TW201416350A (zh) | 2014-05-01 |
UY34902A (es) | 2014-01-31 |
US20140018372A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091722A1 (es) | Forma cristalina de un derivado de indolinona y su uso | |
EA201401054A1 (ru) | N-циклиламиды в качестве нематоцидов | |
MY188447A (en) | Indazole compounds as fger kinase inhibitor, preparation and use thereof | |
TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
UY34885A (es) | Proteínas de unión anti-mesotelina | |
MX2013012979A (es) | Piridina y derivados de pirazina. | |
TWD157169S (zh) | 墨水匣之部分(一) | |
MY161132A (en) | Novel herbicides | |
UA118666C2 (uk) | Похідні піразолу | |
MX2011007998A (es) | Nuevos herbicidas. | |
EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
TWD164994S (zh) | 墨水匣之部分(四) | |
PH12014502294A1 (en) | Triazolo compounds as pde10 inhibitors | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
MX2014014308A (es) | Pirrolidino heterociclos. | |
CR11759A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
MX2016007810A (es) | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. | |
AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
TWD158563S (zh) | 墨水匣之部分(三) | |
MX2016001641A (es) | Ciclobutilcarboxamidas como nematicidas. | |
MY178583A (en) | Hydantoin derivative | |
EA201391586A1 (ru) | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ | |
NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |